- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$73.01

Market cap

$107.11B

P/E Ratio

67.6

Dividend/share

N/A

EPS

$1.08

Enterprise value

$115.35B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,

The EPS has soared by 140% YoY and by 32% from the previous quarter

Boston Scientific's net income has surged by 128% YoY and by 30% QoQ

BSX's quick ratio is down by 17% year-on-year and by 6% since the previous quarter

Boston Scientific's debt has increased by 2.3% QoQ

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.47B

Market cap

$107.11B

Enterprise value

$115.35B

Price to book (P/B)

5.55

Price to sales (P/S)

7.45

EV/EBIT

51.24

EV/EBITDA

33.46

EV/Sales

8.1

Revenue

$14.24B

EBIT

$2.25B

EBITDA

$3.45B

Free cash flow

$1.83B

Per share
Balance sheet
Liquidity

EPS

$1.08

Free cash flow per share

$1.26

Book value per share

$13.16

Revenue per share

$9.8

TBVPS

$10.15

Total assets

$35.14B

Total liabilities

$15.61B

Debt

$9.1B

Equity

$19.28B

Working capital

$1.58B

Debt to equity

0.47

Current ratio

1.32

Quick ratio

0.63

Net debt/EBITDA

2.39

Margins
Efficiency
Dividend

EBITDA margin

24.2%

Gross margin

69.5%

Net margin

11.2%

Operating margin

16.5%

Return on assets

4.6%

Return on equity

8.5%

Return on invested capital

12.5%

Return on capital employed

7.5%

Return on sales

15.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

Intraday

5.83%

1 week

7.43%

1 month

7.97%

1 year

42.21%

YTD

26.29%

QTD

6.6%

How have Boston Scientific's revenue and profit performed over time

Revenue

$14.24B

Gross profit

$9.9B

Operating income

$2.34B

Net income

$1.59B

Gross margin

69.5%

Net margin

11.2%

Boston Scientific's net income has surged by 128% YoY and by 30% QoQ

Boston Scientific's net margin has surged by 104% YoY and by 26% QoQ

Boston Scientific's operating income has increased by 42% YoY and by 9% from the previous quarter

BSX's operating margin is up by 27% year-on-year and by 5% since the previous quarter

What is Boston Scientific's growth rate over time

What is Boston Scientific stock price valuation

P/E

67.6

P/B

5.55

P/S

7.45

EV/EBIT

51.24

EV/EBITDA

33.46

EV/Sales

8.1

The EPS has soared by 140% YoY and by 32% from the previous quarter

The P/E is 13% below the last 4 quarters average of 73.2 and 11% below the 5-year quarterly average of 71.9

The stock's price to book (P/B) is 31% more than its 5-year quarterly average of 4.0 and 25% more than its last 4 quarters average of 4.2

The equity has grown by 10% YoY and by 2.1% from the previous quarter

BSX's P/S is 33% above its 5-year quarterly average of 5.3 and 24% above its last 4 quarters average of 5.7

The revenue has increased by 12% YoY and by 3.5% from the previous quarter

How efficient is Boston Scientific business performance

The return on assets has surged by 130% year-on-year and by 28% since the previous quarter

The return on equity has surged by 130% year-on-year and by 29% since the previous quarter

BSX's ROIC is up by 37% YoY and by 5% from the previous quarter

The ROS has increased by 24% YoY

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 125% more than its total liabilities

BSX's quick ratio is down by 17% year-on-year and by 6% since the previous quarter

BSX's current ratio is down by 13% year-on-year and by 7% since the previous quarter

Boston Scientific's debt is 53% lower than its equity

The equity has grown by 10% YoY and by 2.1% from the previous quarter

Boston Scientific's debt to equity has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.